Healthcare information technology, data mining and data analytics are driving rapid advances in personalized medicine across the country and around the world. The work being done today on this front is but a thin slice of what is yet to come, experts say, and many predict vast advances in the next four to five years.

Elekta has launched a new corporate Web site that provides healthcare professionals, patients, investors and the public with new ways to interact, navigate and browse information about Elekta's solutions for treating cancer and brain disorders.

Emmi Solutions, LLC, creators of Web-based interactive multimedia patient education programs, has collaborated with the American Cancer Society, the nation’s leading voluntary health organization and the preeminent source of cancer information and service, to expand Emmi Solutions’ existing suite of cancer-related programs.

Superior healthcare technology usually means better care and safety for patients - but the familiar technologies that power today's modern hospitals also have a dark side. From infections to cancer to surgical fires, this list covers the top 10 healthcare technology threats for 2010.

In a previous article ("Keys to EHR Team Success," Healthcare IT News; January 12, 2009) we detailed a number of governance structural components which are key to successful electronic health record (EHR) implementation.

IBM is lending its considerable IT expertise to University of North Carolina Health Care to help speed the development of new treatments for diseases like diabetes, cystic fibrosis and cancer.

Three legislators are seeking to create a nationwide demonstration project that would use information technology to gather data on cancer care.

CentraState Medical Center, based in Freehold, New Jersey, has purchased two new state-of-the-art Elekta radiation therapy treatment systems, both with Volumetric Modulated Arc Therapy.

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new breast cancer test that helps physicians identify the probability of a patient's cancer recurring and assess the need for chemotherapy. The new prognostic test, Clarient Insight Dx Breast Cancer Profile, has been clinically validated for women with early-stage, hormone-receptor-positive breast cancer. Unlike other assays used to determine the likelihood of recurrence, the Clarient Insight Dx Breast Cancer Profile uses a combination of pathology risk factors and molecular markers to categorize patients as either high or low risk.